Inhibitors of translation initiation as cancer therapeutics.
about
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancerInfluenza a virus host shutoff disables antiviral stress-induced translation arrestPI3K and cancer: lessons, challenges and opportunitiesThe proteomics of quiescent and nonquiescent cell differentiation in yeast stationary-phase cultures.Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.RNA helicases in infection and disease.Inhibition of translation by cytotrienin A--a member of the ansamycin familyTranslation directed by hepatitis A virus IRES in the absence of active eIF4F complex and eIF2Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response.Translation complex profile sequencing to study the in vivo dynamics of mRNA-ribosome interactions during translation initiation, elongation and termination.Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributorThe DEAD-box helicase eIF4A: paradigm or the odd one out?Hippuristanol reduces the viability of primary effusion lymphoma cells both in vitro and in vivo.Programming cancer cells for high expression levels of Mcl1.Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents.A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis.Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.eIF4B, eIF4G and RNA regulate eIF4A activity in translation initiation by modulating the eIF4A conformational cycle.Stress Granule-Inducing Eukaryotic Translation Initiation Factor 4A Inhibitors Block Influenza A Virus Replication.Non-AUG translation: a new start for protein synthesis in eukaryotes.ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.
P2860
Q28533823-F34E2AF6-97D6-4548-8967-2ACDB5FC6F3FQ28540648-A4529290-53D7-4BD4-B5BB-CAD1AF9D8A9FQ30080017-C8B91BE3-3915-4D94-B87E-3841685FD745Q33810828-045C9714-5FCA-4C9B-97BC-A65130B9BB39Q34105627-D4B3EA91-4DB2-4AE9-98E2-87A2BAD3D459Q34281605-2727126F-8540-41FB-8385-9F4390088D06Q34370125-B8152042-4E47-432C-A1D7-311135899305Q34525975-627D5CAC-837F-4A11-BE40-01D85B3AE8BBQ35944966-A8F574B3-5A27-42A3-AC5C-6B2DF3AF8EDAQ36295149-907B2081-1A10-423D-ADE0-762E7E3701CFQ36347246-45714B44-AFA6-48B2-AC32-C4FB59DFB26CQ36662305-FC99C71D-7B7A-4BEF-A3EF-733135A6CBCFQ37250740-6F1BB150-9A23-4A1A-9170-0D2F0A4D6C0AQ38088109-5167E7FA-31B7-477B-BD56-53589FD62805Q38164843-6CF1DD31-3EA8-4E21-A0A1-A04676CAC40FQ38346557-45D2A2CE-868D-458D-A215-65342EA3F39CQ38711336-FE5766F1-24F9-46DC-9859-C00926CE5DAAQ38808418-4CBAE903-3E27-4772-83BE-1F931514FDA7Q42719837-413B40B1-0ED5-4FEB-965D-36F73F510FE4Q47162522-0C48C7FE-742F-433F-8467-A8CCC323A76CQ47690525-B3888E61-E4B1-497E-82B6-7298E1D575A8Q48011779-AD843680-8B52-4149-ACCB-FB1604FAC173
P2860
Inhibitors of translation initiation as cancer therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibitors of translation initiation as cancer therapeutics.
@en
Inhibitors of translation initiation as cancer therapeutics.
@nl
type
label
Inhibitors of translation initiation as cancer therapeutics.
@en
Inhibitors of translation initiation as cancer therapeutics.
@nl
prefLabel
Inhibitors of translation initiation as cancer therapeutics.
@en
Inhibitors of translation initiation as cancer therapeutics.
@nl
P2860
P356
P1476
Inhibitors of translation initiation as cancer therapeutics.
@en
P2093
Jerry Pelletier
Lisa Lindqvist
P2860
P304
P356
10.4155/FMC.09.122
P577
2009-12-01T00:00:00Z